Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE: Pegzilarginase in Arginase 1 Deficiency
NCT03921541Phase 3Completed
- Sponsor
- Immedica
- Start
- May 2019
- Primary completion
- Feb 2023
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in arginase 1 deficiency (ARG1-D) and hyperargininemia comparing Pegzilarginase with Placebo (2 arms). Primary endpoint: Change From Baseline in Plasma Arginine Concentration at 24 weeks. Started May 2019; status: completed.
02
Drugs
pegzilarginase
03
Conditions
arginase 1 deficiency (ARG1-D)hyperargininemia
Beyond the preview
Go deeper on NCT03921541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03921541.